Arca
Skip to content
Tools
Tools

Glycogen storage disease type ia

Drug research and approvals for glycogen storage disease type ia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 5 studies of glycogen storage disease type ia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 1 approved and 1 open orphan designations naming it.

  • Recruiting worldwide: 5
  • Trials authorized in Canada: 5
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 5 recruiting on ClinicalTrials.gov ↗

Trials authorized in Canada

Newest first; search them all in Canada trials
May 27, 2022An open-label dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MRNA-3745 in participants with glycogen…MRNA-3745Modernatx, Inc.Closed
Oct 8, 2021A phase 3, randomized, double-blind, placebo-controlled study of adenoassociated virus serotype 8-mediated gene transfer of glucose-6- phosphatase in patients…DTX401(AAV8G6PC) / PrednisoloneUltragenyx PharmaceuticalClosed
Jun 1, 2021A phase 1/2 first-in-human, 2-part study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses (part 1: open-label) and repeat…UX053Ultragenyx PharmaceuticalClosed
Jun 4, 2020A long-term follow-up study to evaluate the safety and efficacy of adeno-associated virus (AAV) serotype 8 (AAV8)-mediated gene transfer of…DTX401 (AAV8G6PC)Ultragenyx PharmaceuticalClosed
Jun 29, 2018A phase 1/2, open-label safety and dose-finding study of adeno-associated virus (AAV) serotype 8 (AAV8)-mediated gene transfer of glucose-6-phosphatase…DTX401 (AAV8G6PC)Ultragenyx PharmaceuticalClosed

FDA orphan designations

Approved first, then open designations, newest first
Aug 19, 2026GenglycosTo reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients 8 years of age and older with…Ultragenyx Pharmaceutical, Inc.Approved
Mar 11, 2013AAV-G6Pase vectorTreatment of glycogen storage disease type IaGlyGenix Therapeutics, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.